- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Syncor posts healthy 1998 numbers
Radiopharmaceutical firm Syncor International reported strong financial results this month, posting fourth quarter (end-December) net income of $3.5 million, up from 1997’s $1.7 million. Net sales for the quarter increased 25% to $119 million, up
Radiopharmaceutical firm Syncor International reported strong financial results this month, posting fourth quarter (end-December) net income of $3.5 million, up from 1997s $1.7 million. Net sales for the quarter increased 25% to $119 million, up from $94.8 million. The Woodland Hills, CA, company enjoyed net sales for the year of $449 million, up 18% from $380.6 million in 1997, and net income of $13.9 million, compared with $11.1 million the year before.
Syncor attributed its healthy results to its first price increase in six years, as well as its effort to control costs, which improved its gross margins. The company increased its operating income for its radiopharmacy business in 1998 to $21.4 million, up 64% from $13 million in 1997. In addition, Syncors imaging center subsidiary, Comprehensive Medical Imaging, contributed $37.5 million in sales to the company in fiscal 1998.
New AI-Powered Ultrasound Devices May Enhance Efficiency in Women's Imaging
April 19th 2024One of the features on the new Voluson Signature 20 and 18 ultrasound devices reportedly uses automated AI tools to facilitate a 40 percent reduction in the time it takes to perform second trimester exams.
FDA Approves Fluorescence Imaging System for Detecting Residual Breast Cancer
April 18th 2024The combination of the optical imaging agent Lumisight and the fluorescence imaging device Lumicell Direct Visualization System, collectively known as LumiSystem, reportedly offers 84 percent accuracy with real-time detection of residual breast cancer after lumpectomy procedures.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
